- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Trials to Continue on Promising Drug for some Lymphoma Patients
The trial will test the efficacy of a drug currently called SGN-35, an antibody-drug conjugate (ADC) that, once it gets inside CD30-expressing tumor cells, releases monomethyl auristatin E (MMAE), which kills those cells.
They also plan to begin a phase II study of SGN-35 in early 2009 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).
The President and CEO of Seattle Genetics told therapeuticsdaily.com, “The data thus far from both of our phase I trials of SGN-35 have exceeded our expectations … suggesting that this agent may address a substantial unmet medical need in patients with relapsed or refractory Hodgkin lymphoma.”
Provided the trials go well, Seattle Genetics intends to submit an accelerated new drug application to the FDA for SGN-35 in 2011.